Company Profile

Acetylon Pharmaceuticals Inc
Profile last edited on: 10/20/2023      CAGE: 62EK8      UEI: XGWTDKSW23Z1

Business Identifier: Small molecule drugs: realize therapeutic potential of histone deacetylase
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

Seaport Center 70 Fargo Street Suite 205
Boston, MA 02210
   (617) 245-1300
Location: Single
Congr. District: 08
County: Suffolk

Public Profile

An epigenetics company, Acetylon Pharmaceuticals, Inc. focused on the development of safe, selective inhibitors of histone deacetylases (HDACs) active in the treatment of cancer, neurodegeneration, and other life-threatening diseases. Acetylon’s lead drug candidate, ACY-1215, is currently in clinical trials for the treatment of multiple myeloma. Acetylon's underlying technology was initially developed at the Dana-Farber Cancer Institute and at Harvard University. In 2013 Acetylon entered into a collaboration agreement with Celgene that Celgene the exclusive right to acquire Acetylon at some later point in the future. In December 2016 it was announced that Celgene had acquired the firm. Prior to the consummation of the acquisition, Acetylon spun out a new company, Regenacy Pharmaceuticals, LLC, indicated as being focused on the development of novel drug candidates that selectively regenerate intracellular transport and upregulate gene expression to modify the course of disease. Regenacy received exclusive worldwide rights to Acetylon’s Phase 2 selective histone deacetylase 6 (HDAC6) inhibitor, ricolinostat (ACY-1215), for the treatment of certain non-cancer disease indications including neuropathies, as well as Acetylon’s preclinical selective HDAC1,2 inhibitor candidates and patent families for development in all human disease indications including sickle cell disease and beta-thalassemia.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2013 1 NIH $367,972
Project Title: Selective Hdac1/2 Inhibitors for Hemoglobinopathies

Key People / Management

  Walter C Ogier -- President And Chief Executive Officer

  Jay Bradner -- Founder

  Marc Cohen -- Founder

  Matthew B Jarpe

  Ken Ken -- Founder